

**Extraordinary General
Meeting
29th September 2006**



Chairman's Address



Background

□ Jan 06 RHT Board

- Recognizes FerriScan[®] unlikely to be significant stand alone business
- Retains Montgomery Pacific Group to implement a roll-up of US pathology labs
- Decides to reconstitute Board (completed April 06)



Background

- ❑ May 06 re-constituted Board conduct in-depth review of FerriScan[®] performance and RHT financials
 - FerriScan[®] sales continue to lag projections
 - Unlikely to have sufficient cash to last to end of 2006
- ❑ CEO steps down



Background

□ Board actions taken

- Reduced burn rate (complete May /June)
- Increased FerriScan[®] pricing to major customer through Jan 07 (complete August 06)
- Rights issue to existing shareholders (complete September 06) - \$3,087,989 raised
- Recruit CEO (complete September 06)



RHT CEO

- ❑ Edward D. Dooling, Jr, B.Sc.
- ❑ Extensive US experience marketing, sales, consolidating operations in pathology labs and introducing innovative technologies
 - *Diagnostic Pathology Services*: Executive VP Sales
 - *Asterand*: Chief Operating Officer
 - *AmeriPath*: Vice President and General Manager of Anatomic Pathology
 - *DIANON Systems*: Director of Sales and Marketing



Strategy

- ❑ Pathology lab roll-up
- ❑ Invest in business and technology innovations that are synergistic or complimentary with the path lab network
 - FerriScan[®] & path labs are complimentary - common sales call points



Looking Forward

- ❑ Revise FerriScan[®] commercialization plan
- ❑ Execute pathology lab acquisition/roll-up
 - Supported by Queensland Biotechnology Fund (QBF)
 - QBF supported rights issue (now own ~ 18.9% of RHT)
 - Montgomery Pacific continues evaluation of pathology labs
- ❑ Continue FibroScreen[™] development
- ❑ Identify additional synergistic or complimentary innovations